Profiling of selenomethionine responsive genes in colon cancer by microarray analysis

Cancer Biology and Therapy

Volumn 6, Issue 4, 2007, Pages 494-503

  Goulet, Anne Christine ^a   Watts, George ^a   Lord, Jean L ^a   Nelson, Mark A ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Colon cancer; CX26; DAP 1; Gene expression; Selenomethionine; SGK

Indexed keywords

GLUCOCORTICOID; KALLIKREIN; KALLIKREIN 6; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; PROTEIN ELF3; SELENOMETHIONINE; TRANSCRIPTION FACTOR ELF 1; UNCLASSIFIED DRUG;

ARTICLE; ATOX1 GENE; CANCER CELL; CDH5 GENE; COLON CANCER; CONTROLLED STUDY; DEPP GENE; DNA MICROARRAY; DPYSL2 GENE; EGLN3 GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GJB2 GENE; HUMAN; HUMAN CELL; LIM GENE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PLAU GENE; PRKACB GENE; PXN GENE; SAT GENE; STC2 GENE; TUMOR GENE; VIM GENE; VSNL1 GENE;

EID: 34548231727     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.4.3813     Document Type: Article

References (44)

1. Jass JR. Hyperplastic polyps and colorectal cancer: Is there a link? Clin Gastroenterol Hepatol 2004; 2:1-8.
2. Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther 2004; 3:333-41.
3. Greenwald P, Milner JA, Anderson DE, McDonald SS. Micronutrients in cancer chemoprevention. Cancer Metastasis Rev 2002; 21:217-30.
4. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Estaquio C, Hercberg S. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 2005; 116:182-6.
5. Frank DH, Roe DJ, Chow HH, Guillen JM, Choquette K, Gracie D, Francis J, Fish A, Alberts DS. Effects of a high-selenium yeast supplement on celecoxib plasma levels: A randomized phase II trial. Cancer Epidemiol Biomarkers Prev 2004; 13:299-303.
6. Combs Jr GF. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr 2005; 135:343-7.
7. Clark LC, Combs Jr GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher Jr JL, Park HK, Sanders Jr BB, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial. Nutritional Prevention of Cancer Study Group Jama 1996; 276:1957-63.
8. Klein EA. Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 2004; 1031:234-41.
9. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM. Molecular epidemiologic studies within the Selenium and vitamin E cancer prevention trial (SELECT). Cancer Causes Control 2001; 12:627-33.
10. Polatajko A, Banas B, Encinar JR, Szpunar J. Investigation of the recovery of selenomethionine from selenized yeast by two-dimensional LC-ICP MS. Anal Bioanal Chem 2005; 381:844-9.
11. Baines AT, Holubec H, Basye JL, Thorne P, Bhattacharyya AK, Spallholz J, Shriver B, Cui H, Roe D, Clark LC, Earnest DL, Nelson MA. The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts. Cancer Lett 2000; 160:193-8.
12. Chigbrow M, Nelson M. Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells. Anticancer Drugs 2001; 12:43-50.
13. Baines A, Taylor-Parker M, Goulet AC, Renaud C, Gerner EW, Nelson MA. Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines. Cancer Biol Ther 2002; 1:370-4.
14. Cherukuri DP, Goulet AC, Inoue H, Nelson MA. Selenomethionine regulates cyclooxygenase-2 (COX-2) expression through nuclear factor-kappa B (NF-kappaB) in colon cancer cells. Cancer Biol Ther 2005; 4:175-80.
15. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003; 63:52-9.
16. Wan XS, Zhou Z, Kennedy AR, Kopelovich L. In vitro evaluation of chemopreventive agents using cultured human prostate epithelial cells. Oncol Rep 2003; 10:2009-14.
17. Goulet AC, Chigbrow M, Frisk P, Nelson MA. Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis 2005; 26:109-17.
18. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000; 9:1171-82.
19. Bhamre S, Whitin JC, Cohen HJ. Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth. Prostate 2003; 54:315-21.
20. Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002; 62:2540-5.
21. Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003; 300:357-63.
22. Kingston RE, Narlikar GJ. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev 1999; 13:2339-52.
23. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: Doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 2001; 299:434-41.
24. Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): Interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood 2002; 100:2650-8.
25. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 28:1509-12.
26. El-Bayoumy K, Narayanan BA, Desai DH, Narayanan NK, Pittman B, Amin SG, Schwartz J, Nixon DW. Elucidation of molecular targets of mammary cancer chemoprevention in the rat by organoselenium compounds using cDNA microarray. Carcinogenesis 2003; 24:1505-14.
27. Zhao H, Whitfield ML, Xu T, Botstein D, Brooks JD. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 2004; 15:506-19.
28. Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL. Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem 2003; 278:5871-82.
29. Buse P, Tran SH, Luther E, Phu PT, Aponte GW, Firestone GL. Cell cycle and hormonal control of nuclear-cytoplasmic localization of the serum- and glucocorticoid-inducible protein kinase, Sgk, in mammary tumor cells: A novel convergence point of anti-proliferative and proliferative cell signaling pathways. J Biol Chem 1999; 274:7253-63.
30. Mizuno H, Nishida E. The ERK MAP kinase pathway mediates induction of SGK (serum- and glucocorticoid-inducible kinase) by growth factors. Genes Cells 2001; 6:261-8.
31. Zhang L, Cui R, Cheng X, Du J. Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. Cancer Res 2005; 65:457-64.
32. Bode AM, Dong Z. Inducible covalent posttranslational modification of histone H3. Sci STKE 2005; 2005:re4.
33. Nowak SJ, Corces VG. Phosphorylation of histone H3: A balancing act between chromosome condensation and transcriptional activation. Trends Genet 2004; 20:214-20.
34. Salvador LM, Park Y, Cottom J, Maizels ET, Jones JC, Schillace RV, Carr DW, Cheung P, Allis CD, Jameson JL, Hunzicker-Dunn M. Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells. J Biol Chem 2001; 276:40146-55.
35. Kanczuga-Koda L, Sulkowski S, Koda M, Sulkowska M. Alterations in connexin26 expression during colorectal carcinogenesis. Oncology 2005; 68:217-22.
36. Tanaka M, Grossman HB. Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncol Rep 2004; 11:537-41.
37. Momiyama M, Omori Y, Ishizaki Y, Nishikawa Y, Tokairin T, Ogawa J, Enomoto K. Connexin26-mediated gap junctional communication reverses the malignant phenotype of MCF-7 breast cancer cells. Cancer Sci 2003; 94:501-7.
38. Lee HJ, Lee IK, Seul KH, Rhee SK. Growth inhibition by connexin26 expression in cultured rodent tumor cells. Mol Cells 2002; 14:136-42.
39. Tan LW, Bianco T, Dobrovic A. Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer. Carcinogenesis 2002; 23:231-6.
40. Chen Y, Huhn D, Knosel T, Pacyna-Gengelbach M, Deutschmann N, Petersen I. Downregulation of connexin 26 in human lung cancer is related to promoter methylation. Int J Cancer 2005; 113:14-21.
41. Kanczuga-Koda L, Sulkowski S, Koda M, Skrzydlewska E, Sulkowska M. Connexin 26 correlates with Bcl-xL and Bax proteins expression in colorectal cancer. World J Gastroenterol 2005; 11:1544-8.
42. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 1995; 9:15-30.
43. Feinstein E, Druck T, Kastury K, Berissi H, Goodart SA, Overhauser J, Kimchi A, Huebner K. Assignment of DAP1 and DAPK-genes that positively mediate programmed cell death triggered by IFN-gamma-to chromosome regions 5p12.2 and 9q34.1, respectively. Genomics 1995; 29:305-7.
44. Levy-Strumpf N, Kimchi A. Death associated proteins (DAPs): From gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene 1998; 17:3331-40.